Rathbones Group PLC Sells 4,791 Shares of AbbVie Inc. $ABBV

Posted by Tammy Falkenburg on May 22nd, 2026

Rathbones Group PLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 66,844 shares of the company’s stock after selling 4,791 shares during the period. Rathbones Group PLC’s holdings in AbbVie were worth $15,273,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Chelsea Counsel Co. purchased a new position in shares of AbbVie during the third quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie during the third quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC lifted its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

ABBV stock opened at $214.86 on Friday. The company has a market cap of $379.60 billion, a P/E ratio of 105.84, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32. AbbVie Inc. has a 1 year low of $180.25 and a 1 year high of $244.81. The stock’s fifty day moving average price is $208.95 and its 200-day moving average price is $219.71.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the business posted $2.46 EPS. As a group, analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ABBV shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 target price on shares of AbbVie in a report on Thursday, April 30th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a report on Thursday, April 30th. Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Barclays started coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Check Out Our Latest Report on ABBV

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics unit, received a positive CHMP opinion in Europe for Boey® (trenibotulinumtoxinE) to treat moderate to severe glabellar lines, a step that could expand AbbVie’s aesthetics franchise if formal approval follows. Article: Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Positive Sentiment: AbbVie said it will present new oncology data at ASCO 2026, highlighting momentum across its next-generation cancer pipeline in solid tumors and blood cancers, which supports longer-term growth expectations. Article: AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Positive Sentiment: Piper Sandler reiterated an Overweight rating and raised its price target on AbbVie, citing strength in the company’s inflammatory bowel disease pipeline and Skyrizi-related progress. Article: AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength
Neutral Sentiment: Analyst-style articles on undervaluation may offer some support to investor sentiment, but they do not appear to be direct company-specific catalysts for ABBV. Article: 3 Stocks That May Be Undervalued By The Market In May 2026
Negative Sentiment: AbbVie also faces some headline risk after reports that its patent plea for the hepatitis C drug Mavyret was rejected in India, which could weigh on sentiment around parts of its older portfolio. Article: AbbVie’s Patent Plea for Hepatitis C Therapy Mavyret Rejected in India

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.